Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
Pfizer hires analyst Andrew Baum to manage portfolio strategy
May 6, 2024 11:09am
To boost production of T1D candidates, Vertex jumps to TreeFrog
Apr 24, 2024 7:25am
Leqembi, Takeda, Fujifilm Diosynth—Fierce Pharma Asia
Apr 19, 2024 9:20am
Medincell, AbbVie set out to create new long-acting injectables
Apr 17, 2024 2:49pm
Geopolitical tensions, Carvykti, Enhertu—Fierce Pharma Asia
Apr 12, 2024 8:20am